Cashu Logo
HomeWatchlistNewsSignalsPicks
DJI
+0.08%
SPX
-0.22%
IXIC
-0.51%
FTSE
-0.20%
N225
-0.22%
AXJO
0.00%
Cashu Logo
Log In
HomeWatchlistNewsSignalsPicks
Stocks
0.00 (0.00%)
0.000
USD
At close at --,----
Cashu Logo Alt
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

  • About Us
  • Careers
  • Blog
  • News

Help & Support

  • Help Center
  • Contact Us
  • Pro Support

Legal

  • Privacy Policy
  • Terms of Use
InstagramYouTube

© 2024 Cashu PTY LTD.

Overview

Loading chart...

Key Stats

Market Cap
755.45M
Dividend Yield
0.00%
P/E Ratio
104.19
EPS
0.14
Revenue
105.76M
Avg. Volume
93.39K
Join our newsletter to keep up to date with us!

Recently from Cashu

publisher logo
Cashu

Gyre Therapeutics Monitors SciBase and Castle Biosciences' Strategic Alliance for Atopic Dermatitis

3 days ago
publisher logo
Cashu

Gyre Therapeutics: Breakthrough Bispecific Antibody CM336 Shows Promise for Autoimmune Hemolytic Anemia

6 days ago
publisher logo
Cashu

Gyre Therapeutics Explores Breakthrough Treatment for Autoimmune Hemolytic Anemia with Keymed's CM336

7 days ago

About

What does GYRE do?
Gyre Therapeutics, a San Diego-based biopharmaceutical company with 593 employees, focuses on developing F351 for treating NASH-associated fibrosis and has a pipeline through its indirect interest in Gyre Pharmaceuticals. The company went public on April 12, 2006, and also offers the drug ETUARY.
Sector
💻 Health Care
IPO
CEO
Employees
Headquarters
California, USA
Website
http://www.catalystbiosciences.com
Stocks
Health Care
gyre
Gyre Therapeutics
GYRE
-0.25 (-3.00%)
8.08
USD
At close at Jun 20, 20:41 UTC
Summary
News
Signals
Benchmarks
Financials